Figures & data
Figure 1. 111In-octreotide-szintigraphy before treatment (4 panels left) and during treatment (4 panels right) with Sandostatin LAR™ (after 4 cycles). Arrows show positive receptor status. B. MRI (T1 plus Gadolinium and FLAIR) before treatment (2 panels left) and during treatment (2 panels right) after 4 cycles with Sandostatin LAR™. Arrows show contrast enhancement (T1) and hyperintensity (FLAIR).
![Figure 1. 111In-octreotide-szintigraphy before treatment (4 panels left) and during treatment (4 panels right) with Sandostatin LAR™ (after 4 cycles). Arrows show positive receptor status. B. MRI (T1 plus Gadolinium and FLAIR) before treatment (2 panels left) and during treatment (2 panels right) after 4 cycles with Sandostatin LAR™. Arrows show contrast enhancement (T1) and hyperintensity (FLAIR).](/cms/asset/3fdf8d80-c6c9-4ea8-a1d6-7dce4b80692e/ionc_a_267735_f0001_b.gif)